Teva Pharmaceuticals
TEVA
552 hedge funds and large institutions have $10.5B invested in Teva Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 167 increasing their positions, 181 reducing their positions, and 82 closing their positions.
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
9% more call options, than puts
Call options by funds: $510M | Put options by funds: $467M
4% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 82
0.21% more ownership
Funds ownership: 62.56% → 62.77% (+0.21%)
1% less funds holding
Funds holding: 557 → 552 (-5)
8% less repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 181
23% less capital invested
Capital invested by funds: $13.7B → $10.5B (-$3.18B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$221M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$134M |
| 3 |
BC
Brahman Capital
New York
|
+$101M |
| 4 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$73.8M |
| 5 |
Renaissance Technologies
New York
|
+$71.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$91.2M |
| 2 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$68.9M |
| 3 |
Citigroup
New York
|
-$60.5M |
| 4 |
TA
Teachers Advisors
New York
|
-$52.2M |
| 5 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$46.5M |
TEVA Hedge Fund Activity: Q4 2018 in Review
552 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2018, worth a combined $10.5B — down 23% from $13.7B a quarter earlier.
Buyers outnumbered sellers: 85 funds opened new TEVA positions and 82 closed out — a net gain of 3 holders — while 167 added to existing stakes and 181 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $221M. The largest seller was OppenheimerFunds, exiting entirely with an estimated $91.2M sold.
- 552 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2018, down from 557 in Q3 2018.
- Funds reported $10.5B of Teva Pharmaceuticals stock for Q4 2018, down 23% quarter-over-quarter.
- 85 funds opened new Teva Pharmaceuticals positions in Q4 2018 and 82 closed out, a net change of +3 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2018 was Fidelity Investments, an estimated $221M added.
- The largest Teva Pharmaceuticals seller in Q4 2018 was OppenheimerFunds, an estimated $91.2M sold.
Based on aggregated 13F filings for Q4 2018.